公开(公告)号：US09187748B2

公开(公告)日：2015-11-17

申请号：US14229675

申请日：2014-03-28

申请人： Protiva Biotherapeutics, Inc. ,  Trustees of Boston University ,  United States Army Medical Research and Materiel Command

发明人： Thomas W. Geisbert ,  Amy C. H. Lee ,  Marjorie Robbins ,  Vandana Sood ,  Adam Judge ,  Lisa E. Hensley ,  Ian MacLachlan

IPC分类号： C07H21/04 ,  C12N15/113 ,  A61K9/127 ,  A61K31/713

CPC分类号： C12N15/1131 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2330/51 ,  C12N2760/14111 ,  C12N2310/3521

摘要： The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

摘要翻译： 本发明提供包含针对埃博拉病毒（EBOV）基因表达的治疗性核酸（例如干扰RNA（例如siRNA））和使用这种组合物沉默EBOV基因表达的方法的组合物。 更具体地说，本发明提供了沉默EBOV基因表达的未修饰和化学修饰的干扰RNA及其使用方法，例如用于预防或治疗由一种或多种EBOV物种如扎伊尔EBOV引起的EBOV感染。 本发明还提供包含一种或多种干扰RNA分子，阳离子脂质和非阳离子脂质的血清稳定核酸 - 脂质颗粒，其可以进一步包含抑制颗粒聚集的共轭脂质。 还提供了通过向哺乳动物受试者施用一种或多种干扰RNA分子来沉默EBOV基因表达的方法。

公开(公告)号：US20160264971A1

公开(公告)日：2016-09-15

申请号：US14880082

申请日：2015-10-09

申请人： PROTIVA BIOTHERAPEUTICS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY ,  UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND

发明人： THOMAS W. GEISBERT ,  Amy C.H. Lee ,  Marjorie Robbins ,  Vandana Sood ,  Adam Judge ,  Lisa E. Hensley ,  Ian MacLachlan

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1131 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2330/51 ,  C12N2760/14111 ,  C12N2310/3521

摘要： The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

公开(公告)号：US20150111945A1

公开(公告)日：2015-04-23

申请号：US14229675

申请日：2014-03-28

申请人： Protiva Biotherapeutics, Inc. ,  Trustees of Boston University ,  United States Army Medical Research and Materiel Command

发明人： Thomas W. Geisbert ,  Amy C.H. Lee ,  Marjorie Robbins ,  Vandana Sood ,  Adam Judge ,  Lisa E. Hensley ,  Ian MacLachlan

IPC分类号： C12N15/113 ,  A61K9/127 ,  A61K31/713

CPC分类号： C12N15/1131 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2330/51 ,  C12N2760/14111 ,  C12N2310/3521

摘要： The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

摘要翻译： 本发明提供包含针对埃博拉病毒（EBOV）基因表达的治疗性核酸（例如干扰RNA（例如siRNA））和使用这种组合物沉默EBOV基因表达的方法的组合物。 更具体地说，本发明提供了沉默EBOV基因表达的未修饰和化学修饰的干扰RNA及其使用方法，例如用于预防或治疗由一种或多种EBOV物种如扎伊尔EBOV引起的EBOV感染。 本发明还提供包含一种或多种干扰RNA分子，阳离子脂质和非阳离子脂质的血清稳定核酸 - 脂质颗粒，其可以进一步包含抑制颗粒聚集的共轭脂质。 还提供了通过向哺乳动物受试者施用一种或多种干扰RNA分子使EBOV基因表达沉默的方法。